Cargando…

Gender Differences in Medication Use: A Drug Utilization Study Based on Real World Data

A gender-specific drug utilization study was performed in the Campania region, Southern Italy. Data were based on outpatient drug prescriptions collected from administrative databases. The study population included all patients with at least one drug prescription in 2018. Prevalence was used as a me...

Descripción completa

Detalles Bibliográficos
Autores principales: Orlando, Valentina, Mucherino, Sara, Guarino, Ilaria, Guerriero, Francesca, Trama, Ugo, Menditto, Enrica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312791/
https://www.ncbi.nlm.nih.gov/pubmed/32492925
http://dx.doi.org/10.3390/ijerph17113926
_version_ 1783549812172390400
author Orlando, Valentina
Mucherino, Sara
Guarino, Ilaria
Guerriero, Francesca
Trama, Ugo
Menditto, Enrica
author_facet Orlando, Valentina
Mucherino, Sara
Guarino, Ilaria
Guerriero, Francesca
Trama, Ugo
Menditto, Enrica
author_sort Orlando, Valentina
collection PubMed
description A gender-specific drug utilization study was performed in the Campania region, Southern Italy. Data were based on outpatient drug prescriptions collected from administrative databases. The study population included all patients with at least one drug prescription in 2018. Prevalence was used as a measure to estimate the degree of exposure to drugs. A total of 3,899,360 patients were treated with at least one drug (54.2% females). The number of prescriptions was higher in females than males (55.6% vs. 44.4%). Females recorded higher prevalence for the majority of therapeutic groups (ATC II—anatomical therapeutic chemical), as well as for anti-inflammatory and antirheumatic products drugs (M01) (25.6% vs. 18.7%, risk ratio (RR): 0.73), beta blocking agents (C07) (14.5% vs. 11.6%, RR: 0.80), psychoanaleptics (N06) (7.1% vs. 3.7%, RR: 0.52), and antianemic preparations (B03) (2.8% vs. 6.7%, RR: 0.4). Higher prevalence was identified for males only for drugs used in diabetes (A10) (6.8% vs. 6.2%, RR: 1.1), particularly for biguanides (A10BA). Conversely, treatment duration was longer among males, explaining the higher mean cost per treated patient. This real-world study showed substantial gender differences in terms of medication use and duration of treatment and costs. These results are relevant to promoting and supporting the emerging role of precision and personalized medicine.
format Online
Article
Text
id pubmed-7312791
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73127912020-06-26 Gender Differences in Medication Use: A Drug Utilization Study Based on Real World Data Orlando, Valentina Mucherino, Sara Guarino, Ilaria Guerriero, Francesca Trama, Ugo Menditto, Enrica Int J Environ Res Public Health Article A gender-specific drug utilization study was performed in the Campania region, Southern Italy. Data were based on outpatient drug prescriptions collected from administrative databases. The study population included all patients with at least one drug prescription in 2018. Prevalence was used as a measure to estimate the degree of exposure to drugs. A total of 3,899,360 patients were treated with at least one drug (54.2% females). The number of prescriptions was higher in females than males (55.6% vs. 44.4%). Females recorded higher prevalence for the majority of therapeutic groups (ATC II—anatomical therapeutic chemical), as well as for anti-inflammatory and antirheumatic products drugs (M01) (25.6% vs. 18.7%, risk ratio (RR): 0.73), beta blocking agents (C07) (14.5% vs. 11.6%, RR: 0.80), psychoanaleptics (N06) (7.1% vs. 3.7%, RR: 0.52), and antianemic preparations (B03) (2.8% vs. 6.7%, RR: 0.4). Higher prevalence was identified for males only for drugs used in diabetes (A10) (6.8% vs. 6.2%, RR: 1.1), particularly for biguanides (A10BA). Conversely, treatment duration was longer among males, explaining the higher mean cost per treated patient. This real-world study showed substantial gender differences in terms of medication use and duration of treatment and costs. These results are relevant to promoting and supporting the emerging role of precision and personalized medicine. MDPI 2020-06-01 2020-06 /pmc/articles/PMC7312791/ /pubmed/32492925 http://dx.doi.org/10.3390/ijerph17113926 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Orlando, Valentina
Mucherino, Sara
Guarino, Ilaria
Guerriero, Francesca
Trama, Ugo
Menditto, Enrica
Gender Differences in Medication Use: A Drug Utilization Study Based on Real World Data
title Gender Differences in Medication Use: A Drug Utilization Study Based on Real World Data
title_full Gender Differences in Medication Use: A Drug Utilization Study Based on Real World Data
title_fullStr Gender Differences in Medication Use: A Drug Utilization Study Based on Real World Data
title_full_unstemmed Gender Differences in Medication Use: A Drug Utilization Study Based on Real World Data
title_short Gender Differences in Medication Use: A Drug Utilization Study Based on Real World Data
title_sort gender differences in medication use: a drug utilization study based on real world data
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312791/
https://www.ncbi.nlm.nih.gov/pubmed/32492925
http://dx.doi.org/10.3390/ijerph17113926
work_keys_str_mv AT orlandovalentina genderdifferencesinmedicationuseadrugutilizationstudybasedonrealworlddata
AT mucherinosara genderdifferencesinmedicationuseadrugutilizationstudybasedonrealworlddata
AT guarinoilaria genderdifferencesinmedicationuseadrugutilizationstudybasedonrealworlddata
AT guerrierofrancesca genderdifferencesinmedicationuseadrugutilizationstudybasedonrealworlddata
AT tramaugo genderdifferencesinmedicationuseadrugutilizationstudybasedonrealworlddata
AT mendittoenrica genderdifferencesinmedicationuseadrugutilizationstudybasedonrealworlddata